ライフサイエンスコーパス: B-cell leukemia

1 ed by the t(1;19) translocation in human pre-B cell leukemia.

2 nized anti-CD22 mAb having been used against B cell leukemia.

3 re-BCR) signaling, spontaneously develop pre-B cell leukemia.

4 innate immunity to virally induced acute pro-B cell leukemia.

5 gens have been studied for the management of B-cell leukemia.

6 manner in a Nalm-6 xenograft rodent model of B-cell leukemia.

7 x and mEg5 contributes to the development of B-cell leukemia.

8 oncogene product, v-Abl, and also causes pre-B-cell leukemia.

9 ients with lymphoma than in those with acute B-cell leukemia.

10 of miR-125b in mice can promote myeloid and B-cell leukemia.

11 mplying a role in the pathogenesis of mature B-cell leukemia.

12 favorable outcome in patients with precursor B-cell leukemia.

13 s well as in a subset of patients with acute B-cell leukemia.

14 with peripheral blood eosinophila and T- or B-cell leukemias.

15 of the IL-2R in T-cell leukemias and p75 in B-cell leukemias.

16 the most frequent genetic alteration in AKXD B-cell leukemias.

17 plicated in the development of childhood pre-B-cell leukemias.

18 not been detected in patients with human pre-B-cell leukemias.

19 ibition as a potential therapeutic target in B-cell leukemias.

20 they up-regulated the antiapoptotic protein B-cell leukemia 2 (Bcl-2) by 10-fold.

21 ld down-regulated in MCL; in addition to the B-cell leukemia 2 (BCL2) system other apoptotic pathways

22 duced expression of the proapoptotic protein B-cell leukemia 2 homology 3 (BH3) interacting domain de

23 leukemia sequence-1 (MCL1), an antiapoptotic B cell leukemia-2 family member.

24 ia-1 (Mcl-1), an antiapoptotic member of the B-cell leukemia-2 family, is an important participant in

25 enotype (35%) or a lethal, short-latency pre-B-cell leukemia (20%).

26 B cell leukemia 3 (Bcl-3) is an essential negative regul

27 Lipopolysaccharide (LPS)-induced B cell leukemia 3 (Bcl3) expression was strongly impaire

28 on of NR4A1 and NR4A3 in chronic lymphocytic B-cell leukemia (71%), in follicular lymphoma (FL, 70%),

29 ly for multiple myeloma, but also for mature B cell leukemia and lymphoma.

30 Clinical trials in patients with advanced B cell leukemias and lymphomas treated with CD19-specifi

31 impressive results in treating patients with B cell leukemias and lymphomas.

32 inical concepts to target the BCR pathway in B-cell leukemia and lymphoma.

33 n younger than 6 years of age with precursor B-cell leukemia and no adverse genetic features had a 10

34 for the epigenetic changes that occur in pre-B-cell leukemia and other B-cell-related diseases.

35 ed from the bone marrow of patients with pre-B-cell leukemias and these findings should facilitate th

36 We report the identification of B cell leukemia (Bcl)-3 as an essential negative regulat

37 nd modulated by virus-encoded anti-apoptotic B cell leukemia (BCL)2-like suppressors.

38 We report here the identification of B-cell leukemia (Bcl)-3 as a modulator of innate immune

39 monstrated that miR-125b induces myeloid and B-cell leukemia by inhibiting interferon regulatory fact

40 model for an inducible and reversible acute B-cell leukemia caused by p210 BCR/ABL.

41 In this study, we show that B cell leukemia causes T cells to become activated and h

42 Earlier work with the DT40 chicken B cell leukemia cell line showed that Syk was required t

43 pment, and is expressed in a number of human B cell leukemia cell lines, primary human chronic myeloi

44 ute promyelocytic leukemia (APL) and chronic B-cell leukemia cell lines, respectively.

45 In human B cell leukemia cells, binding of wild-type PAX5 to a re

46 cts of RAR and RXR rexinoids in human T- and B-cell leukemia cells and demonstrated that RXR rexinoid

47 In pre B cell leukemias containing the t(1;19) chromosome trans

48 AX5-ETV6 as a potent oncoprotein that drives B-cell leukemia development.

49 Pre-B cell leukemia homeobox 1 (Pbx1)-d is a dominant-negati

50 Pre-B-cell leukemia homeobox (PBX) and myeloid ecotropic vir

51 Pre-B-cell leukemia homeobox (PBX) transcription factors are

52 Pre-B-cell leukemia homeobox (Pbx)-regulating protein-1 (Pre

53 otein (PBXIP1/HPIP) is a co-repressor of pre-B-cell leukemia homeobox 1 (PBX1) and is also known to r

54 id ecotropic viral integration 1 (Meis1)/pre-B-cell leukemia homeobox 3 (Pbx3) genes.

55 Pre-B-cell leukemia homeobox interacting protein 1 or human

56 oteins competitively heterodimerize with pre-B-cell leukemia homeobox-1 (Pbx1).

57 us modified binding of the proadipogenic pre-B-cell leukemia homeobox-1/homeobox 9 complex.

58 The v-Cbl oncogene induces myeloid and B-cell leukemia; however, the mechanism by which transfo

59 s in vitro, while inducing predominantly pre-B cell leukemias in vivo.

60 ase in childhood megakaryocyte-erythroid and B-cell leukemia in Down syndrome implicates trisomy 21 (

61 Activated ABL oncogenes cause B-cell leukemias in mice and chronic myelogenous leukemi

62 were frequent in patients with other mature B-cell leukemias in which CD20 surface expression is inc

63 gnancies, but are consistently absent in pre-B cell leukemias induced by the chimeric oncoprotein E2a

64 Thus, B cell leukemia-induced inhibition of T cell Akt/mTORC1

65 the product of a proto-oncogene in acute pre-B-cell leukemia, is a global regulator of embryonic deve

66 2B1-D1 and the parental 12B1 line, but not a B-cell leukemia line, A20.

67 s (IFNs)-alpha/beta and -gamma, whereas, pro-B-cell leukemia lines derived from Emu-ret mice are mark

68 inhibitor, synergized to induce apoptosis in B cell leukemia, lymphoma, and multiple myeloma.

69 such as TNFR-associated factors 2 and 5 and B cell leukemia/lymphoma 10, were readily decreased upon

70 Myeloid cell leukemia sequence 1 (MCL-1) and B cell leukemia/lymphoma 2 (BCL-2) are anti-apoptotic pr

71 4, expression of the anti-apoptotic molecule B cell leukemia/lymphoma 2 (Bcl-2), and enhanced IL-2 pr

72 eukemia 1 (Mcl1) but not other antiapoptotic B cell leukemia/lymphoma 2 (Bcl2) family members.

73 Antiapoptotic B cell leukemia/lymphoma 2 (BCL2) family proteins are ex

74 gher percentage of CD44(v.low) cells express B cell leukemia/lymphoma 2, interleukin-7 receptor, and

75 we show that the transcriptional coregulator B cell leukemia/lymphoma 3 (Bcl3) limits granulopoiesis

76 e Kruppel-like transcription factor 6 (KLF6)-B cell leukemia/lymphoma 6 (BCL6) signaling axis as a no

77 Here, we report that B cell leukemia/lymphoma 6 (BCL6), a transcriptional rep

78 at potentiates transcriptional repression by B cell leukemia/lymphoma 6 (BCL6).

79 rus, which encodes v-Abl/p160, induces a pre-B cell leukemia/lymphoma in mice.

80 deletions and mutations in Bcl11b (encoding B cell leukemia/lymphoma-11B) and identify the presence

81 nd truncating temperature-induced changes in B cell leukemia/lymphoma-2 associated X protein alpha an

82 t key repressors of the plasmacytic program, B cell leukemia/lymphoma-6 and paired box gene 5, are re

83 Using a murine B-cell leukemia/lymphoma (BCL1) model, we showed the dev

84 Upregulation of cyclin D1/B-cell leukemia/lymphoma 1 (CCND1/BCL1) is present in mo

85 ed cyclin D1 expression and progression of a B-cell leukemia/lymphoma 1 tumor in mice by preferential

86 ion and utilizes the adaptor molecule BCL10 (B-cell leukemia/lymphoma 10).

87 In apoptosis, the B-cell leukemia/lymphoma 2 (Bcl-2) family members Bcl-2-

88 hese tumors are genetically characterized by B-cell leukemia/lymphoma 2 (BCL2) translocation and muta

89 and tensin homolog, TGFbeta receptor II, and B-cell leukemia/lymphoma 2 -associated X protein.

90 parallel decrease in anti-apoptotic protein B-cell leukemia/lymphoma 2 levels.

91 factor profile, with elevated expression of B-cell leukemia/lymphoma 6 (Bcl-6), CXC chemokine recept

92 trast, inhibitory cyclin G2, p27/Cdkn1b, and B-cell leukemia/lymphoma 6 (Bcl6) were sharply down-modu

93 body-dependent cellular cytotoxicity against B-cell leukemia/lymphoma cell lines and primary chronic

94 odel consisting of highly disseminated human B-cell leukemia/lymphoma was developed by i.v. inoculati

95 Using a mouse model of B-cell leukemia/lymphoma, we find that differences in tr

96 The B-cell leukemia/lymphoma-2 (BCL-2) family of proteins go

97 Purpose B-cell leukemia/lymphoma-2 (BCL-2) overexpression is com

98 ), endothelial nitric oxide synthase (eNOS), B-cell leukemia/lymphoma-2 (Bcl-2), and inducible nitric

99 ceptor-associated factor-1 (TRAF-1), TRAF-2, B-cell leukemia/lymphoma-2 (Bcl-2), Bcl-x, A1, and cellu

100 ciated with colorectal cancer formation (eg, B-cell leukemia/lymphoma-2 [Bcl2]) and 1.8% (18/906) wit

101 Moreover, EGCG suppressed the proteins B-cell leukemia/lymphoma-2 protein (Bcl-2), X-linked inh

102 ular assay for the study of therapy of human B-cell leukemia/lymphoma.

103 Transgenic mice that over-express B cell leukemia/lymphomas (Bcl)-2 in myeloid cells under

104 Thus, precursor B-cell leukemias maintain evolution at the IgH locus at

105 transduced T cells efficiently lysed primary B-cell leukemia, mantle cell lymphoma, and multiple myel

106 ip in B cell diseases, especially in chronic B cell leukemia, needs to be considered further in regar

107 Hairy cell leukemia (HCL) is a chronic B-cell leukemia noted for an indolent course that ultima

108 ificantly more common in patients with other B-cell leukemias, occurring in five (50%) of 10 patients

109 ecreased, and neurotensin was unexpressed in B cell leukemia patient's cells, as compared with health

110 ) chromosomal translocation of pediatric pre-B cell leukemia produces chimeric oncoprotein E2a-Pbx1,

111 genome-scale shRNA screen for modulators of B-cell leukemia progression in vivo.

112 myelocytic leukemia zinc finger protein, and B-cell leukemia protein 6.

113 ll activating factor, BAFF) developed CD5(+) B-cell leukemia resembling human chronic lymphocytic leu

114 d leukemia, and the t(12;21)(p13;q22) in pre-B-cell leukemia, respectively.

115 We show that loss of Phf6 in B-cell leukemia results in systematic changes in gene ex

116 These anti-pre-B-cell leukemia-specific CTL lysed both unstimulated and

117 w here the generation of autologous anti-pre-B-cell leukemia-specific cytolytic T-cell lines from the

118 ed iNKT cell cytotoxicity against T-cell and B-cell leukemia targets in vitro and iNKT-cell-mediated

119 x1, E2a-Pbx1, is an oncoprotein in human pre-B cell leukemia that strongly suppresses differentiation

120 he transcriptional activation of IL10 by pre-B cell leukemia transcription factor-1b and another Hox

121 eletion of CDH-implicated genes encoding pre-B cell leukemia transcription factors (Pbx) led to letha

122 Pre-B cell leukemia transcription factors (PBXs) act as cofa

123 otropic viral insertion site (MEIS), and pre-B-cell leukemia transcription factor 1 (PBX) may regulat

124 nhibitors showed that the homeoproteins, pre B-cell leukemia transcription factor 1 (PBX1) and PBX-re

125 CDKIs, we observed a cellular gene, the pre-B-cell leukemia transcription factor 1 (Pbx1) gene, down

126 out mice for one of the candidate genes, pre-B-cell leukemia transcription factor 1 (Pbx1), and ident

127 ind to DNA or a key HOX-binding partner, pre-B-cell leukemia transcription factor-1 (PBX1).

128 without altering the genomic DNA and induces B-cell leukemia via genetic deletion of the gene encodin

129 a dramatic increase in the frequency of pro-B cell leukemia was observed in mice with combined heter

130 ng a humanized model of treatment refractory B cell leukemia, we find that infiltration of leukemia c

131 most importantly primary Bcr-Abl-transformed B-cell leukemias were completely eradicated by the alloa

132 T cells from patients with acute or chronic B cell leukemia, which were also metabolically exhausted

133 c B-cell lymphoma and, upon transplantation, B-cell leukemia with leukemic infiltrates in liver and l

134 therapy, whereas patients who have precursor B-cell leukemia without other adverse features appear to

135 -AHPC-mediated cleavage of the antiapoptotic B-cell leukemia XL (Bcl-XL) protein to a proapoptotic 18

136 NF-kappaB-dependent antiapoptotic proteins, B-cell leukemia XL (Bcl-XL), Bcl-2, X-linked inhibitor o